Zwitterionic modification can prolong the blood circulation time of nanocarrier in vivo, but zwitterionic content will affect the functions of nanocarrier such as enzyme-responsive and intracellular or extracellular delivery. Therefore, it is necessary to explore the relationship between the zwitterionic content and circulation time of nanocarrier so as to figure out what content of zwitterion can enable the nanocarrier to obtain both the long blood circulation ability and other functions mentioned above. Herein, using nanocapsule as a research model, we investigated the nanocapsule modified with zwitterion of phosphorylcholine (PC) or carboxybetaine (CB) respectively, and through 1H-NMR quantification we determined the zwitterionic surface content, so as to study the effect of PC or CB surface content on blood circulation performance of nanocapsule. In vivo study showed that the nanocapsule possessed an optimal surface filling ratios range for blood circulation of 43–68% for PC and of 20–68% for CB, with the longest t1/2=37.35 h for PC-nanocapsule and t1/2=45.27 h for CB-nanocapsule. Furthermore, the protein adsorption and macrophage endocytosis experiments indicated that when the surface filling ratio reached 43% for PC-nanocapsule and 20% for CB-nanocapsule, it could effectively reduce the protein adsorption and weaken macrophage endocytosis, thus explaining the phenomenon of long circulation time of nanocapsules from the point of protein adsorption and interaction with immune cells. This study proposes a new direction for designing long-circulating nanocarrier, and provides basis for constructing enzyme-responsive and intracellular or extracellular delivery platform.
ZamaniMAghajanzadehMRostamizadehK, et al.
In vivo study of poly (ethylene glycol)-poly (caprolactone)-modified folic acid nanocarriers as a pH responsive system for tumor-targeted co-delivery of tamoxifen and quercetin. J Drug Deliv Sci Tec2019;
54: 101283.
2.
MaedaHWuJSawaT, et al.
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release2000;
65: 271–284.
3.
FangJNakamuraHMaedaH.The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev2011;
63: 136–151.
4.
MaedaHBharateGYDaruwallaJ.Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm2009;
71: 409–419.
5.
GreishKFangJInutsukaT, et al.
Macromolecular therapeutics – advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet2003;
42: 1089–1105.
6.
MatsumuraYMaedaH.A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res1986;
46: 6387–6392.
7.
MaedaH.The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul2001;
41: 189–207.
8.
LiBYuanZZhangP, et al.
Zwitterionic nanocages overcome the efficacy loss of biologic drugs. Adv Mater2018;
30: 1705728.
9.
YeLZhangYYangB, et al.
Zwitterionic-modified starch-based stealth micelles for prolonging circulation time and reducing macrophage response. ACS Appl Mater Interfaces2016;
8: 4385–4398.
10.
LiuRLiYZhangZ, et al.
Drug carriers based on highly protein-resistant materials for prolonged in vivo circulation time. Regen Biomater2015;
2: 125–133.
11.
ShaoQJiangS.Molecular understanding and design of zwitterionic materials. Adv Mater Weinheim2015;
27: 15–26.
12.
YangWLiHWZhangJ, et al.
Pursuing “zero” protein adsorption of poly (carboxybetaine) from undiluted blood serum and plasma. Langmuir2009;
25: 11911–11916.
13.
ChenSZhengJLiL, et al.
Strong resistance of phosphorylcholine self-assembled monolayers to protein adsorption: insights into nonfouling properties of zwitterionic materials. J Am Chem Soc2005;
127: 14473–14478.
14.
HeYHowerJChenS, et al.
Molecular simulation studies of protein interactions with zwitterionic phosphorylcholine self-assembled monolayers in the presence of water. Langmuir2008;
24: 10358–10364.
15.
ZhangPSunFTsaoC, et al.
Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity. Proc Natl Acad Sci USA2015;
112: 12046–12051.
16.
InoueYIshiharaK.Reduction of protein adsorption on well-characterized polymer brush layers with varying chemical structures. Colloids Surf B Biointerfaces2010;
81: 350–357.
17.
LinWMaGWuJ, et al.
Different in vitro and in vivo behaviors between Poly (carboxybetaine methacrylate) and poly (sulfobetaine methacrylate). Colloids Surf B Biointerfaces2016;
146: 888–894.
18.
LewisATangYBrocchiniS, et al.
Poly (2-methacryloyloxyethyl phosphorylcholine) for protein conjugation. Bioconjug Chem2008;
19: 2144–2155.
19.
WangQLeiDChenF, et al.
Tracing difference: in vitro and in vivo antitumor property comparison of pH-sensitive biomimetic phosphorylcholine micelles with insensitive micelles. ACS Biomater Sci Eng2019;
5: 2258–2270.
20.
ZhangXChenWZhuX, et al.
Encapsulating therapeutic proteins with polyzwitterions for lower macrophage nonspecific uptake and longer circulation time. ACS Appl Mater Interfaces2017;
9: 7972–7978.
21.
LiangSLiuYJinX, et al.
Phosphorylcholine polymer nanocapsules prolong the circulation time and reduce the immunogenicity of therapeutic proteins. Nano Res2016;
9: 1022–1031.
DobrovolskaiaMAAggarwalPHallJB, et al.
Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm2008;
5: 487–495.
24.
WalkeyCDOlsenJBGuoH, et al.
Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc2012;
134: 2139–2147.
25.
ZhangZZhangMChenS, et al.
Blood compatibility of surfaces with superlow protein adsorption. Biomaterials2008;
29: 4285–4291.
26.
LaddJZhangZChenS, et al.
Zwitterionic polymers exhibiting high resistance to nonspecific protein adsorption from human serum and plasma. Biomacromolecules2008;
9: 1357–1361.
27.
ZhangLXueHCaoZ, et al.
Multifunctional and degradable zwitterionic nanogels for targeted delivery, enhanced MR imaging, reduction-sensitive drug release, and renal clearance. Biomaterials2011;
32: 4604–4608.
28.
JiangSCaoZ.Ultralow‐fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications. Adv Mater Weinheim2010;
22: 920–932.
29.
HanDQiHHuangK, et al.
The effects of surface charge on the intra-tumor penetration of drug delivery vehicles with tumor progression. J Mater Chem B2018;
6: 3331–3339.
30.
YanMGeJLiuZ, et al.
Encapsulation of single enzyme in nanogel with enhanced biocatalytic activity and stability. J Am Chem Soc2006;
128: 11008–11009.
31.
WeiWDuJLiJ, et al.
Construction of robust enzyme nanocapsules for effective organophosphate decontamination, detoxification, and protection. Adv Mater Weinheim2013;
25: 2212–2218.
32.
ZhangLLiuYLiuG, et al.
Prolonging the plasma circulation of proteins by nano-encapsulation with phosphorylcholine-based polymer. Nano Res2016;
9: 2424–2432.
33.
LiuCWenJMengY, et al.
Efficient delivery of therapeutic miRNA nanocapsules for tumor suppression. Adv Mater Weinheim2015;
27: 292–297.
34.
WiarachaiOVilaivanTIwasakiY, et al.
Clickable and antifouling platform of poly [(propargyl methacrylate)-ran-(2-methacryloyloxyethyl phosphorylcholine)] for biosensing applications. Langmuir2016;
32: 1184–1194.
35.
ZhangZVaisocherovaHChengG, et al.
Nonfouling behavior of polycarboxybetaine-grafted surfaces: structural and environmental effects. Biomacromolecules2008;
9: 2686–2692.
36.
PanSChenMWuL.Synthesis of raspberry-like polymer/SiO2 hybrid colloidal spheres grafted by block-copolymer poly (MPC-b-MPS) for underwater superoleophobic anti-biofouling coatings. J Colloid Interface Sci2018;
522: 20–28.
37.
ZhangZChenSJiangS.Dual-functional biomimetic materials: nonfouling poly (carboxybetaine) with active functional groups for protein immobilization. Biomacromolecules2006;
7: 3311–3315.
38.
LundqvistMStiglerJEliaG, et al.
Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci USA2008;
105: 14265–14270.
39.
YamaokaKNakagawaTUnoT.Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm1978;
6: 547–558.
40.
ZhouHFanZLiPY, et al.
Dense and dynamic polyethylene glycol shells cloak nanoparticles from uptake by liver endothelial cells for long blood circulation. ACS Nano2018;
12: 10130–10141.
41.
WangJAsgharSJinX, et al.
Mitoxantrone-loaded chitosan/hyaluronate polyelectrolyte nanoparticles decorated with amphiphilic PEG derivates for long-circulating effect. Colloids Surf B Biointerfaces2018;
171: 468–477.
42.
WangJAsgharSYangL, et al.
Chitosan hydrochloride/hyaluronic acid nanoparticles coated by mPEG as long-circulating nanocarriers for systemic delivery of mitoxantrone. Int J Biol Macromol2018;
113: 345–353.
43.
ChengTZhangYLiuJ, et al.
Ligand-switchable micellar nanocarriers for prolonging circulation time and enhancing targeting efficiency. ACS Appl Mater Interfaces2018;
10: 5296–5304.
44.
AmoozgarZYeoY.Recent advances in stealth coating of nanoparticle drug delivery systems. Wiley Interdiscip Rev Nanomed Nanobiotechnol2012;
4: 219–233.
45.
GrefRLüCkMQuellecP, et al.
Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces2000;
18: 301–313.
46.
SofiaSJPremnathVVMerrillEW.Poly(ethylene oxide) grafted to silicon surfaces: grafting density and protein adsorption. Macromolecules1998;
31: 5059–5070.
47.
OwensDEPeppasNA.Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm2006;
307: 93–102.
48.
YangZHGallowayJAYuHU.Protein interactions with poly(ethylene glycol) self-assembled monolayers on glass substrates: diffusion and adsorption. Langmuir1999;
15: 8405–8411.
49.
LengCHungHCSunS, et al.
Probing the surface hydration of nonfouling zwitterionic and PEG materials in contact with proteins. ACS Appl Mater Interfaces2015;
7: 16881–16888.
50.
ChenSLiLZhaoC, et al.
Surface hydration: principles and applications toward low-fouling/nonfouling biomaterials. Polymer2010;
51: 5283–5293.
51.
LeungBOYangZWuSSH, et al.
Role of interfacial water on protein adsorption at cross-linked polyethylene oxide interfaces. Langmuir2012;
28: 5724–5728.
52.
CorboCMolinaroRParodiA, et al.
The impact of nanoparticle protein corona on cytotoxicity, immunotoxicity and target drug delivery. Nanomedicine (Lond)2016;
11: 81–100.
53.
LichtnekertJKawakamiTParksWC, et al.
Changes in macrophage phenotype as the immune response evolves. Curr Opin Pharmacol2013;
13: 555–564.
54.
StolnikSIllumLDavisSS.Long circulating microparticulate drug carriers. Adv Drug Deliver Rev1995;
16: 195–214.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
